

Key Features

| Name | Alpha Balanced Fund |
|-----------------|---|
| APIR Code | ETL4308AU |
| Inception Date | 30 December 2021 |
| Benchmark | Morningstar AUS Balanced Target Allocation NR \$A |
| Peer Group | Australia Fund Multisector Balanced |
| Mgmt Costs | 0.69% p.a. |
| Buy/Sell Spread | 0.25% / 0.25% |
| Platforms | PlatformplusWRAP |
| Fund Size | \$2.2m |

Monthly Commentary

The Alpha Balanced Fund had a total return of -1.56% (net of fees) in October 2023, which was above the Morningstar Australian Balanced Target Allocation Index by +0.44% and Peer Group Median by +0.18%.


October was the second consecutive tough month for all asset classes except Cash, with International and Australian Shares down as reporting season got underway in the USA. For the Fund, the key contributors were Large US Technology Shares (including Microsoft, Amazon, Meta Platforms and Apple), Energy Infrastructure Shares (including Williams Companies and Cheniere Energy) and a selection of Healthcare stocks (led by Novo Nordisk and Eli Lilly). Footwear designer and distributor, Deckers Outdoor, which owns iconic Australian brand UGG boots, was another major winner and was up +18% for the month.

The main detractors were in Australia, with Office Property landlord, Dexus, being the biggest loser. It was down -11% due to higher bond yields, softening asset values and the announced impending departure of CEO Darren Steinberg. Transport and logistics company, Brambles, was another loser and was down -8% for the month. While the Fund had some winners in Healthcare, there were also some losers, with Sanofi and Fresenius Medical Care falling -14% and -19% respectively.

The Fund's exposure to long-dated sovereign Bonds continued to detract, as bond yields rose again in October. While the size of this position has reduced in recent months, exposure to Bonds has still been retained in the Fund to help counterbalance our overweight allocation in Shares, as Bonds are likely to rally if we go into recession.

The Fund remains overweight to Growth Assets despite our concerns about the impact of higher interest rate on the economy. The positions held in the Fund are mostly of higher quality and it is hoped that they would be less susceptible if the economy were to go into a slowdown. We were less active in terms of making changes in October than in previous months, which reflects the material outperformance of our selections in Growth Assets since February, with and Technology and Healthcare still being the key overweights. Conversely, the Fund currently holds just one US Bank (JPMorgan), underweight allocation to European Financials and no exposure to US Listed Property, which appear to be the most vulnerable sectors to higher bond yields.

Performance




| Portfolio Performance | 1mth | 3mth | 6mth | 1yr | Inception |
|-----------------------------|---------|-----------|----------------|--------------|-----------|
| Alpha Balanced Fund | -1.56% | -3.64% | -2.32% | 0.92% | 0.77% |
| Benchmark | -2.00% | -4.40% | -2.98% | 2.74% | -3.85% |
| Peer Group Median | -1.74% | -3.99% | -2.59% | 2.91% | -3.12% |
| Disclaimer: Not performance | figuros | ara chown | after all foor | and ovnoncou | accumina |

Disclaimer: Net performance figures are shown after all fees and expenses, assuming reinvestment of distributions. Past performance is not an indicator of future performance. Returns for periods 1 year or greater are calculated on an annualised basis. **Peer Group Median**: Morningstar Category: Australian Multisector – Balanced

Source: Morningstar Direct (to 31 October 2023)

Asset Class Exposures



Top 10 Holdings

| Security | Ticker | Country | Weight |
|--------------------------------|--------|---------------|--------|
| BHP Group | BHP | Australia | 3.1% |
| National Australia Bank | NAB | Australia | 2.0% |
| Microsoft Corp | MSFT | United States | 1.7% |
| Alphabet | GOOGL | United States | 1.3% |
| Commonwealth Bank of Australia | CBA | Australia | 1.3% |
| Wesfarmers | WES | Australia | 1.1% |
| Apple | AAPL | United States | 1.0% |
| Cheniere Energy | LNG | United States | 1.0% |
| Goodman Group | GMG | Australia | 0.9% |
| Novo Nordisk | NVO | United States | 0.9% |

Your financial adviser will take the time to discuss this report with you and answer any questions you may have.

alphafundmanagers.com.au Alpha Fund Managers Pty Ltd

AFS Licence 236523 ABN: 37 124 085 883 DISCLOSURE: Equity Trustees Limited ("Equity Trustees") ABN 46 004 031 298 | AFSL 240975, is the Responsible Entity for the Alpha Balanced Fund ("Fund"). Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a publicly listed company on the Australian Securities Exchange (ASX: EQT). Alpha Fund Managers is a corporate authorized representative of Alpha Investment Management Pty Ltd ABN 13 122 381 908 (AFSL 307379). Both of these companies are wholly owned subsidiaries of Infocus Wealth Management Limited ABN 28 103 551 015. This publication has been prepared to provide general information only. In preparing this information, Alpha did not take into account the investment objectives, financial situation or particular needs of any particular person. It is not intended to take the place of professional advice and you should not take action on specific issues in reliance on this information. Neither Equity Trustees, Alpha, nor any of their related parties, their employees or directors, provide any warranty of accuracy or reliability in relation to such information or accept any liability to any person who relies on it. Past performance should not be taken as an indicator of future performance. You should obtain a copy of the Product Disclosure Statement before making a decision about whether to invest in this product. The relevant Target Market Determination (TMD) is also available via www.alphafundmanagers.com.au. This document may include general commentary on market activity, sector trends or other broad-based economic or political conditions that should not be taken as investment advice. Information stated herein about specific securities is subject to change. Any reference to specific securities should not be taken as a recommendation to buy, sell or hold these securities. While the information contained in this document has been prepared with reasonable care, no responsibility or liability is accepted for any errors or omissions or misstatements however caused.